AtaiBeckley plans phase 3 trials for depression drug in Q2 2026

March 10, 2026 6:00 AM

AtaiBeckley Inc. (NASDAQ: ATAI) announced plans to initiate two parallel Phase 3 studies for BPL-003, a nasal spray treatment for ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found